
Search
Filter Results
Displaying 81–90 of 1065 results
-
Nov 14, 2024
Strengthening research in retinal disease with record-breaking $19.8 million investment in innovative projects targeting vision loss worldwide.
-
Nov 13, 2024
Atsena’s LCA1 Gene Therapy Licensed by Nippon Shinyaku for Markets in US and Japan
The companies are planning a Phase 3 clinical trial for the promising gene therapy.
-
Mutations in CRB1 are a relatively common cause of several inherited retinal degenerations, including: Leber congenital amaurosis (LCA) retinitis pigmentosa (RP), and macular dystrophy (MD).
-
Funded Foundation Fighting Blindness Grants and Awards for Fiscal Year 2024 (July 1, 2023 – June 30, 2024)
-
Oct 30, 2024
BlueRock’s Photoreceptor Cell Therapy to Move into Clinical Trial
The Foundation funded Dr. David Gamm for development of the induced pluripotent stem cell approach to be used in the trial.
-
General thank you message for registering for an upcoming event.
-
Oct 29, 2024
Kiora Receives Authorization for Phase 2 Clinical Trial of its Photoswitch for Advanced RP
The 36-participant trial will take place at multiple sites in Australia.
-
Oct 25, 2024
The RD Fund Announces Ocuphire Pharma’s Acquisition of Opus Genetics
The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD).
-
Oct 25, 2024
Eye on the Cure Podcast | Episode 75: Sharon King
Sharon King, co-founder and president of Taylor’s Tale, talks to host Ben Shaberman about her family’s journey when her daughter Taylor was diagnosed with Batten disease.
-
Ongoing Foundation Fighting Blindness national webinars around the latest research for blinding diseases.